76 / 84
76
alpha treatment on admissions to hospital and days
of sick leave in patients with ankylosing spondylitis.
Ann Rheum Dis 2004;63:1670-2.
36. van der Heijde D, Dijkmans B, Geusens P, Sieper
J, DeWoody K, Williamson P, et al. Ankylosing
Spondylitis Study for the Evaluation of
Recombinant Infliximab Therapy Study Group.
Efficacy and safety of infliximab in patients with
ankylosing spondylitis: results of a randomized,
placebo-controlled trial (ASSERT). Arthritis Rheum
2005;52:582-91.
37. Braun J, Brandt J, Listing J, Zink A, Alten R,
Burmester G, et al. Two year maintenance of
efficacy and safety of infliximab in the treatment of
ankylosing
spondylitis.
Ann
Rheum
Dis
2005;64:229-34.
38. Braun J, Baraliakos X, Brandt J, Listing J, Zink A,
Alten R, et al. Persistent clinical response to the anti-
TNF-alpha antibody infliximab in patients with
ankylosing spondylitis over 3 years. Rheumatology
(Oxford) 2005;44:670-6.
39. Braun J, Baraliakos X, Listing J, Fritz C, Alten R,
Burmester G, et al. Persistent clinical efficacy and
safety of anti-tumour necrosis factor alpha therapy
with infliximab in patients with ankylosing
spondylitis over 5 years: evidence for different types
of response. Ann Rheum Dis 2008;67:340-5.